GlassScriptPhysician profile
David K Hafen
NPI 1134238207
$2,834.88
in general payments reported to CMS, 2019-2025
31 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $245 · 2021: $304 · 2022: $514 · 2023: $559 · 2024: $444 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,214.34 | 2020-2025 | |
| Lilly USA, LLC | $233.03 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $149.23 | 2019-2025 | |
| Amgen INC. | $133.41 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $116.90 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $100.78 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.68 | 2019-2025 | Jardiance |
| Allergan, INC. | $90.45 | 2019-2020 | |
| Tris Pharma INC | $77.36 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $76.81 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $73.23 | 2020-2023 | Qelbree |
| Cranial Technologies, INC | $55.20 | 2023-2024 | Doc Band |
| Boston Scientific Corporation | $52.09 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $47.65 | 2020-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $36.93 | 2023-2024 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.08 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $31.40 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.73 | 2021 | |
| Mylan Specialty L.P. | $22.33 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.83 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.47 | 2022 | |
| Neurelis, INC. | $16.25 | 2024 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2023 | Livalo, Seglentis |
| Seqirus USA INC | $14.93 | 2022 | |
| Dynavax Technologies Corporation | $13.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.39 | 2019 | |
| Sobi, INC | $12.29 | 2019 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Organon LLC | $12.17 | 2025 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hafen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.